A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma
Abstract Background Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) require multi‐modality treatment. Immune checkpoint inhibitors (ICIs) are now standard of care in management of recurrent/metastatic HNSCC. However, its role in the definitive and neoadjuvant setting rem...
Main Authors: | Udit Nindra, Joshua Hurwitz, Dion Forstner, Venessa Chin, Richard Gallagher, Jia Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-05-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.5815 |
Similar Items
-
Challenges in Combining Immunotherapy with Radiotherapy in Recurrent/Metastatic Head and Neck Cancer
by: Gaber Plavc, et al.
Published: (2020-10-01) -
Intratumoral CD103+CD8+ T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma
by: Siqi Ren, et al.
Published: (2023-10-01) -
Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study
by: Wenwu He, et al.
Published: (2022-06-01) -
Neoadjuvant chemoimmunotherapy in locally advanced gastric or gastroesophageal junction adenocarcinoma
by: Xiao Liu, et al.
Published: (2024-04-01) -
Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas
by: Kai Wang, et al.
Published: (2023-07-01)